Ginkgo Bioworks
DNA
313 hedge funds and large institutions have $1.51B invested in Ginkgo Bioworks in 2023 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 103 increasing their positions, 80 reducing their positions, and 47 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
29% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 80
9% more call options, than puts
Call options by funds: $4.29M | Put options by funds: $3.93M
0.05% less ownership
Funds ownership: 1.86% → 1.81% (-0.05%)
6% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 47
2% less funds holding
Funds holding: 320 → 313 (-7)
10% less capital invested
Capital invested by funds: $1.68B → $1.51B (-$166M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$127M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$32.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.8M |
| 4 |
Morgan Stanley
New York
|
+$12.6M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$6.96M |
| 2 |
Two Sigma Investments
New York
|
-$2.96M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$2.41M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$2.07M |
| 5 |
Goldman Sachs
New York
|
-$2M |
DNA Hedge Fund Activity: Q1 2023 in Review
313 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q1 2023, worth a combined $1.51B — down 9.9% from $1.68B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of DNA and 44 opened new positions — a net loss of 3 holders — while 80 trimmed existing stakes and 103 added.
The largest buyer was Viking Global Investors, adding an estimated $127M. The largest seller was First Trust Advisors, exiting entirely with an estimated $6.96M sold.
- 313 institutional investors held Ginkgo Bioworks (DNA) as of Q1 2023, down from 320 in Q4 2022.
- Funds reported $1.51B of Ginkgo Bioworks stock for Q1 2023, down 9.9% quarter-over-quarter.
- 44 funds opened new Ginkgo Bioworks positions in Q1 2023 and 47 closed out, a net change of -3 holders.
- The largest Ginkgo Bioworks buyer in Q1 2023 was Viking Global Investors, an estimated $127M added.
- The largest Ginkgo Bioworks seller in Q1 2023 was First Trust Advisors, an estimated $6.96M sold.
Based on aggregated 13F filings for Q1 2023.